Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

Retatrutide, a new experimental weight-loss drug, targets three hormones and shows promising results far beyond current ...

Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Major stock indexes ended mixed Thursday, with the Dow Jones Industrial Average and S&P 500 closing at record highs but the ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...